What is the CanAssist Breast test?

CanAssist Breast is a prognostic test that helps predict the risk of breast cancer recurrence and supports oncologists in personalizing treatment plans.

Who can benefit from the CanAssist Breast test?

It is suitable for patients diagnosed with early-stage, hormone receptor-positive breast cancer to determine their recurrence risk.

How accurate is the CanAssist Breast test?

CanAssist Breast has been validated on South Asian and Caucasian populations, demonstrating high accuracy in predicting recurrence risk.

Breast Cancer Recurrence Test, CanAssistBreast, India

BMC Cancer Part of Springer Nature

Scientific Publication by OncoStem

February, 2021

Multi-country clinical validation of CanAssist Breast in Europe indicates robustness of the test

View

Cancer Medicine

Scientific Publication by OncoStem

October, 2020

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX

View

BMC Cancer Part of Springer Nature

Scientific Publication by OncoStem

August, 2020

Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients

View

JCO Global Oncology

Scientific Publication by Renowned Oncologists Worldwide

June, 2020

Gouri Shankar Bhattacharyya et al: Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective

View

American Society of Clinical Oncology

Scientific Publication by OncoStem

May, 2020

Canassist breast: An affordable breast cancer prognostic test validated on Asian patients

View

International Journal of Molecular and Immuno Oncology

Scientific Publication by Renowned Oncologists Worldwide

May, 2020

Arvind Krishnamurthy: Breast cancer prognostic tools: A promising Indian option

View

International Journal of Molecular and Immuno Oncology

Scientific Publication by Renowned Oncologists Worldwide

May, 2020

Purvish Parikh et al: Why we should rely only on molecular tests based on Indian data

View

Scientific Publications